Therapy Areas: Cardiovascular
Ascletis selects once-monthly SQ GLP-1R/GIPR dual peptide agonist, ASC35, for clinical development
13 October 2025 - Hong Kong-based Ascletis Pharma Inc (HKEX: 1672) has selected ASC35, a once-monthly, potentially best-in-class subcutaneously (SQ) administered GLP-1 receptor (GLP-1R)/GIP receptor (...
Lundbeck's bexicaserin granted Breakthrough Therapy Designation in China to treat seizures in severe rare epilepsies
13 October 2025 - Danish pharmaceutical company H. Lundbeck A/S (CPH:HLUN-A) announced on Monday that its investigational drug bexicaserin, for the treatment of seizures associated with Developmental ...
Autonomix Medical secures new US patent to expand precision nerve-targeted therapies
9 October 2025 - US medical device company Autonomix Medical, Inc. (NASDAQ: AMIX) announced on Thursday that it has been granted a patent from the United States Patent and Trademark Office covering sy...
Merck completes acquisition of Verona Pharma to expand cardio-pulmonary portfolio
7 October 2025 - US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, announced on Tuesday that it has completed the acquisition of Verona Pharma plc (Nasda...
Amgen offers Repatha through AmgenNow direct-to-patient programme
7 October 2025 - US-based biopharmaceutical company Amgen (NASDAQ: AMGN) announced on Monday the launch of AmgenNow, a new direct-to-patient programme starting with Repatha (evolocumab).This follows r...
MedHub-AI's AutocathFFR receives national reimbursement approval in Japan
6 October 2025 - Israeli medical technology company MedHub-AI announced on Friday that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved national reimbursement for the company�...